Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTC:MDNAF), a clinical-stage immunothera...
Company's T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportun...
New data from the Phase 1 dose-escalation and evaluation portion of the trial will be presented at the Society of Immunotherapy...
- Durable anti-cancer activity was observed during monotherapy dose escalation without dose-limiting toxicities - Late-stage...
- Additional evidence of durable anti-cancer activity with MDNA11 monotherapy seen in latest radiographic scans from first four...
- Patent covers methods of treating cancer with an IL-2 Superkine and PD1/PDL1 or CTLA-4 checkpoint inhibitor, administered in ...
Guggenheim analyst Charles Zhu initiates coverage on Medicenna Therapeutics (TSX:MDNA) with a Buy rating and announces Price...
- MDNA11's selectivity and dose-dependent stimulation of anti-cancer immune cells indicates potential for increased anti-tu...
-- Single agent Anti-PD1-IL-2 BiSKIT™ showed superior efficacy compared to a combination of an anti-PD1 antibody with an IL-2 S...
